Back to Research Hub
UroGen Pharma Ltd.
URGN
$42.53-1.08 (-2.49%)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant…
StreetsValue research for UroGen Pharma Ltd. (URGN)
Members get the full report for UroGen Pharma Ltd.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.